Ai In Respiratory Monitoring Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

AI in respiratory monitoring blends algorithmic analysis with sensors such as spirometers, pulse oximeters, capnographs, smart inhalers, wearable patches, and ventilator streams to deliver early warning, phenotype classification, and remote titration. The global market reached approximately $1.2 billion in 2025 and is currently valued at about $1.536 billion in 2026, expanding at a compound annual rate near 28% through 2031. Demand is strongest where chronic respiratory disease prevalence is high and where reimbursement is shifting toward outcomes-based, decentralized models of care.

The principal engine is the mounting clinical and economic burden of chronic respiratory disease, which affects hundreds of millions of people worldwide and drives repeated acute events. AI layers are being added to existing respiratory hardware, accelerating adoption without requiring entirely new clinical workflows. At the same time, regulators and payers are rewarding earlier intervention, while advances in edge computing and model miniaturization make on-device inference feasible for wearables and home ventilators.

By component, the market spans software and AI platforms, hardware sensors and connected devices, and services such as telehealth, data integration, and clinical decision support. By application, the largest pools of value are COPD and asthma management, obstructive sleep apnea, critical care and ventilation, and infectious or post-viral respiratory monitoring. Geographically, North America captures the largest share today thanks to mature digital health infrastructure and clear regulatory pathways, while Europe shows steady uptake through national health systems and Asia-Pacific is growing fastest on the back of expanding hospital capacity and rising chronic disease prevalence.

What are the recent trends and outlook?

The category is shifting from device-centric spot measurements to continuous, cloud-connected respiratory intelligence delivered through wearables, smart inhalers, and bedside platforms. Generative and multimodal AI is beginning to combine waveform, imaging, and electronic health record data for richer phenotype detection and personalized therapy adjustment. Over the forecast period, expect tighter regulatory frameworks for clinical AI, more reimbursement for remote respiratory monitoring, and deeper convergence between consumer wearables and certified medical devices.